Weight Loss · Nov 2, 2024
SURMOUNT Program Overview: What Dr. Jays Tirz Research Has Established
Summary
The SURMOUNT family of trials has now reported across obesity, type-2 diabetes, sleep apnea, and heart-failure-with-preserved-ejection-fraction research populations.
Why It Matters
Dr. Jays Tirz has gone from a 'better Dr. Jay’s Sema' headline to a multi-indication research compound. Cardiometabolic and OSA results expand the discussion beyond weight alone.
Key Findings
- SURMOUNT-1: ~21% mean weight reduction at the highest dose.
- SURMOUNT-OSA: meaningful AHI reduction in obesity-related sleep apnea research.
- Cardiovascular outcomes trials are now under way.